DNLI - Secarna Pharma inks research pact with Denali for neurodegenerative therapies

Germany-based Secarna Pharmaceuticals has signed a research and option agreement with Denali Therapeutics ([[DNLI]] -0.5%), under which, the companies will leverage former's LNAplus antisense oligonucleotide discovery platform and later's blood-brain barrier against neurodegenerative diseases. Financial terms were not disclosed.Under the terms, Secarna will receive an undisclosed target-based technology access fee. Following the discovery and lead selection phase, Denali has a target-based option to in-license the respective development programs. If Denali exercises an option, Secarna will receive an option exercise fee, as well as milestone payments and tiered royalties.

For further details see:

Secarna Pharma inks research pact with Denali for neurodegenerative therapies